Xiran Medical, Dubbed 'China's Alcon,' Secures Tens of Millions RMB in Series Angel Funding Led by Taiyu Investment with Yiran Capital as Exclusive Financial Advisor

VCBeat has learned that Xiran Medical recently completed an angel round of financing amounting to tens of millions of RMB, with Taiyu Investment as the sole investor and Yiran Capital serving as the exclusive financial advisor.

Zhang Chi, Founder of Xiran Medical, stated:

High-end ophthalmic surgical equipment serves as an indispensable partner for ophthalmic surgeons, driving innovation and transformation in eye surgery while functioning as the core platform for clinical applications and scientific research. Xiran Medical is committed to the research, development, and manufacturing of high-quality, safe, and reliable ophthalmic surgical devices and consumables through medical-engineering collaboration and clinically guided R&D. Additionally, the company provides comprehensive one-stop training services related to surgical procedures for ophthalmic surgeons. This round of financing will be allocated to the R&D and regulatory registration of the company’s core ophthalmic products.

Dr. Ji Tianrong, Founder of Taiyu Investment, stated:

As China’s population ages and myopia among adolescents becomes more prevalent, the number of ophthalmic consultations has steadily risen, driving rapid growth in the ophthalmic healthcare market. Ophthalmology has long been a key focus area for Taiyu Investment. The team at Xiran Medical boasts extensive experience in the R&D and commercialization of ophthalmic medical devices. Its products are designed to align with the procedural preferences of Chinese ophthalmologists, holding promise to break the monopoly of foreign giants in niche segments and provide better, more cost-effective options for patients in China.

Hao Fangran, Partner at Yiran Capital, stated:

The ophthalmology sector is undoubtedly one of the most promising areas for investment in the medical device industry. High-end ophthalmic surgical equipment possesses strong hard-tech attributes and offers substantial potential for import substitution, poised to become another golden market following intraocular lenses (IOLs) and orthokeratology (OK) lenses. Xiran Medical boasts the top-tier team in China in this field, and we look forward to witnessing the rise of the “Chinese Alcon” as it sets sail!

Taiyu Investment, established in 2014, is an independent professional venture capital firm under Tigermed, a publicly listed company. Taiyu Investment focuses on equity investments in early-stage and growth-stage healthcare companies. Its management team possesses extensive expertise in the pharmaceutical and healthcare industries, broad industry resources, and rich investment experience. To date, it has completed early-stage equity investments totaling over RMB 1 billion across more than 70 projects, primarily serving as a lead investor in Seed or Pre-A rounds. Its investment portfolio covers medical devices, biopharmaceuticals, health supplements, and CRO enterprises. By empowering its portfolio companies, Taiyu Investment creates value for the development of the healthcare industry in China and globally, contributing to public health.

Yiran Capital was established in 2020. The team is dedicated to providing comprehensive, in-depth financing services to high-quality healthcare enterprises in the fields of innovative drugs, medical devices (IVD), and healthcare services. With a precise grasp of industry trends, the firm possesses extensive experience in project capital operations and market execution.